Immune to Cancer: The CRI Blog




Dr. Jill O’Donnell-Tormey Discusses the Latest Developments in Immunological Technologies 

CRI’s CEO and Director of Scientific Affairs, Dr. Jill O’Donnell-Tormey, recently spoke with ecancer about recent developments of immunological technologies that improve patient outcomes in treatment, control, and cancer prevention.  

Although the field has experienced significant progress in recent years, Dr. O’Donnell-Tormey says we can achieve further progress by, “…supporting excellent scientists, and giving them the resources they need to explore questions… this is where major leaps in our understanding and in the development of new drugs that are using your immune system will come from.”  

This content was originally published on ecancer. 

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.